Study guide
MacTel and radiation retinopathy
European Board of Ophthalmology Diploma EBOD
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: EBOD Examination, Applications and Regulations
EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals
2 Chapter 2: Physical Optics, Photometry and Lenses
Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid
3 Chapter 3: Instrument Optics, Aberrations and Laser Physics
Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT
4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing
Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses
5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation
Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics
6 Chapter 6: Extraocular Anatomy and Motor Physiology
Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys
7 Chapter 7: Binocular Vision and Amblyopia
Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment
8 Chapter 8: Childhood Assessment and Strabismus Testing
Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts
9 Chapter 9: Esotropia, Exotropia and Vertical Deviations
Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew
10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery
Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles
11 Chapter 11: ROP and Paediatric Ocular Disease
Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding
12 Chapter 12: Ocular Surface Anatomy and Infection
Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis
13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation
Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis
14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies
Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies
15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure
Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency
16 Chapter 16: Surface Reconstruction and Keratoplasty
Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems
17 Chapter 17: Lens Development, Cataract Assessment and Biometry
Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry
18 Chapter 18: IOL Planning and Phacoemulsification
Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques
19 Chapter 19: Cataract Anaesthesia and Surgical Complications
Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO
20 Chapter 20: Corneal and Intraocular Refractive Surgery
Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange
21 Chapter 21: Presbyopia Procedures and Surface Therapeutics
Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin
22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy
Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation
23 Chapter 23: Angle, Disc and Visual-Field Assessment
Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry
24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms
Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure
25 Chapter 25: POAG, Angle Closure and Pigmentary Disease
POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma
26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment
Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers
27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion
Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions
28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy
Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis
29 Chapter 29: Inherited Retina and Electrophysiology
Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina
30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid
AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum
31 Chapter 31: Retinal Breaks and Detachment Repair
PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling
32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma
Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment
33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation
SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation
34 Chapter 34: Infectious Uveitis and Endophthalmitis
Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment
35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy
Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison
36 Chapter 36: Papilloedema, IIH and Afferent Localisation
Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization
37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology
Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies
38 Chapter 38: Central Motor Control and Cranial Nerve Palsies
Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus
39 Chapter 39: Myasthenia and Ocular Myopathy
Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome
40 Chapter 40: Pupillary Pathways and Anisocoria
Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials
41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment
Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation
42 Chapter 42: Lid Repair and Lacrimal Drainage
Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR
43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours
Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma
44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease
Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling
45 Chapter 45: Ocular Trauma and Vascular Systemic Disease
Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease
46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology
Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects
47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations
Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal
MacTel and radiation retinopathy
Key Takeaways Explain This Topic AI
MacTel type 2 involves neurodegeneration as well as vascular changes, and cavitation differs from ordinary exudative oedema.
Treat neovascular complications separately from the underlying nonproliferative MacTel process.
Radiation retinopathy and neuropathy depend on tissue exposure and latency, with treatment directed to the complication.
Last updated: October 2026
Macular Telangiectasia (MacTel): Type 1 vs. Type 2
Macular telangiectasia comprises two clinically, epidemiologically, and pathologically distinct entities:
MacTel Type 1 (Unilateral Aneurysmal Telangiectasia)
Demographics: Unilateral in 98% of cases; striking predilection for males in the fourth to fifth decades of life (mean age ~40 years). Considered an abortive or localized macular variant of Coats disease.
Pathophysiology: Primary vascular telangiectasia of the temporal macular capillary network. Dilated, ectatic capillaries, microaneurysms, and localized lipid exudation produce chronic macular oedema and exudative visual loss.
Clinical Presentation: Metamorphopsia and moderate visual loss ( 6 / 12 6/12 6/12 to 6 / 36 6/36 6/36 ). Slit-lamp biomicroscopy reveals prominent telangiectatic capillaries and aneurysms in the temporal half of the macula, surrounded by circinate rings of yellow lipid hard exudates and cystoid macular oedema.
Therapeutic Response: Responds favourably to targeted focal argon laser photocoagulation directed at leaking aneurysms, as well as intravitreal anti-VEGF or dexamethasone implants.
MacTel Type 2 (Bilateral Idiopathic Perifoveal Telangiectasia)
Demographics: Bilateral, symmetric, acquired disorder manifesting in the fifth to seventh decades (mean age 55–60 years). Equal gender distribution or slight female predominance. Highly associated with systemic metabolic syndrome, hypertension, and type 2 diabetes.
The Paradigm Shift: A Neurodegenerative Disorder: Extensive clinicopathological research demonstrates that MacTel Type 2 is NOT a primary retinal vascular disease . Rather, it is a primary neurodegenerative disease of Müller glial cells . Loss of Müller cell footplates in the fovea leads to secondary depletion of macular xanthophyll pigments (lutein and zeaxanthin), progressive photoreceptor apoptosis, and tertiary microvascular ectasia and cavitation.
Multimodal Clinical Features:
Biomicroscopy: Subtle loss of retinal transparency (grayish opalescence) often most prominent to the temporal juxtafoveolar area ; superficial refractile crystalline deposits in ~50% of eyes; dilated, blunted right-angled venules that plunge perpendicularly into deep retinal layers; late stellate hyperpigmentation plaques (pigment hyperplasia).
Absence of Lipid: In sharp contrast to MacTel Type 1 and diabetic retinopathy, prominent lipid hard exudates are completely absent in uncomplicated MacTel Type 2.
Optical Coherence Tomography (SD-OCT): Demonstrates the characteristic "ILM Drape" —the internal limiting membrane remains structurally intact, draping over empty, hyporeflective cavitations in the inner and outer retina without overall retinal thickening. Focal disruption of the ellipsoid zone (EZ) and external limiting membrane occurs, progressing to full-thickness macular holes (which lack surrounding subretinal fluid cuffs).
Fluorescein Angiography: Early telangiectatic capillary dilatation limited to the temporal perifoveolar network; late diffuse ectatic hyperfluorescent staining without classical petaloid cystoid pooling.
Confocal Blue Reflectance: Reveals a distinct, oval zone of hyper-reflectance centered temporally to the fovea.
Dual-Wavelength Autofluorescence: Demonstrates characteristic loss of normal central luteal pigment absorption.
Complications & Therapy:
Non-Neovascular Stage: Anti-VEGF is not routine treatment for the non-neovascular neurodegeneration; avoid destructive macular laser. Neither addresses the underlying photoreceptor loss. Emerging therapy: Encapsulated cell biodelivery implants secreting Ciliary Neurotrophic Factor (CNTF / NT-501) significantly slow photoreceptor loss.
Neovascular Stage: Secondary subretinal choroidal/retinal neovascularisation (SRNV / CNV) develops in ~10% to 15% of eyes, causing acute subretinal haemorrhage. Unlike the non-neovascular phase, secondary CNV responds dramatically to intravitreal anti-VEGF injections.
Radiation Retinopathy & Radiation Optic Neuropathy
Radiation retinopathy is a delayed-onset, slowly progressive, occlusive microangiopathy resulting from exposure of the retina to ionizing radiation.
Etiology & Dosimetry
Radiation Sources:
Ophthalmic Plaque Brachytherapy: Iodine-125 ( 125 I ^{125}\text{I} 125 I ), Ruthenium-106 ( 106 Ru ^{106}\text{Ru} 106 Ru ), or Palladium-103 ( 103 Pd ^{103}\text{Pd} 103 Pd ) episcleral plaques utilized for the treatment of uveal melanoma, circumscribed choroidal haemangioma, or retinoblastoma.
External Beam Radiotherapy (EBRT) & Particle Beam Therapy: Proton beam irradiation, stereotactic radiosurgery (Gamma Knife / CyberKnife), or fractionated EBRT for head, neck, paranasal sinus, nasopharyngeal, or orbital malignancies.
Radiation Threshold & Latency:
Risk depends on total dose, fractionation, irradiated retinal volume, tumour location, diabetes and other treatment. Published series do not establish one universally safe retinal threshold or a fixed retinopathy percentage for every eye receiving the same nominal dose.
Latency Period: Characteristically delayed, with clinical manifestations typically emerging between 6 months and 3 years (peak onset at 18 to 36 months ) post-irradiation.
Accelerating Factors: Systemic hypertension, diabetes mellitus, and concurrent chemotherapy (e.g., 5-fluorouracil, cisplatin) significantly lower the radiation tolerance threshold and accelerate disease onset.
Molecular Pathology & Fundus Features
Ionizing radiation induces double-stranded DNA breaks in slowly dividing vascular endothelial cells, provoking cellular senescence, endothelial swelling, and apoptosis. The microvascular sequelae are clinically and angiographically identical to diabetic retinopathy : Ionizing Radiation ⟹ Endothelial Apoptosis ⟹ Capillary Occlusion ⟹ Severe Retinal Ischaemia ⟹ VEGF Upregulation \text{Ionizing Radiation} \implies \text{Endothelial Apoptosis} \implies \text{Capillary Occlusion} \implies \text{Severe Retinal Ischaemia} \implies \text{VEGF Upregulation} Ionizing Radiation ⟹ Endothelial Apoptosis ⟹ Capillary Occlusion ⟹ Severe Retinal Ischaemia ⟹ VEGF Upregulation
Clinical Signs: Cotton-wool spots (nerve fibre layer infarcts), microaneurysms, telangiectatic vessels, intraretinal flame and blot haemorrhages, hard exudates, and radiation macular oedema (RMO) .
Proliferative Complications: Extensive capillary non-perfusion on fluorescein angiography stimulates secondary neovascularisation of the disc (NVD), retina (NVE), and iris (rubeosis iridis), leading to vitreous haemorrhage and tractional retinal detachment.
Radiation Optic Neuropathy (RON): Occurs when the anterior optic nerve receives > 50 Gy >50\,\text{Gy} > 50 Gy ; presents with sudden, painless, catastrophic visual loss, swollen hyperaemic optic disc, peripapillary splinter haemorrhages, and subsequent optic atrophy.
Evidence-Based Management Protocols
Intravitreal Anti-VEGF Therapy: First-line treatment for radiation macular oedema (RMO). Anti-VEGF injections (aflibercept, ranibizumab, bevacizumab) administered on a proactive treat-and-extend schedule significantly decrease central foveal thickness and stabilize visual acuity.
Prophylactic Anti-VEGF Therapy: Selected cohort evidence supports scheduled injections after plaque treatment in defined populations. Interpret the comparator, follow-up and visual endpoint; this does not establish one compulsory prophylactic regimen for all forms of ocular irradiation.
Intravitreal Dexamethasone Implants: Effective adjuvant therapy, particularly in vitrectomised or refractory eyes.
Laser : Treat retinal neovascularisation and selected severe ischaemic complications according to specialist assessment. Nonperfusion alone does not impose a universal prophylactic laser rule.
Management Depends on Stage and Jurisdiction
Selected Coats disease without leakage threatening vision can be observed; leaking telangiectasia may need laser or cryotherapy, and detached retinas may require specialised drainage or surgery. Stage alone does not prescribe an identical operation. MacTel type 2 is primarily neurodegenerative with characteristic vascular and outer-retinal changes; anti-VEGF is used for associated neovascular complications, not routine treatment of non-neovascular cavitation. ENCELTO, an encapsulated cell implant delivering ciliary neurotrophic factor, received US FDA approval for adults with idiopathic MacTel type 2 on 5 March 2025. This is a US authorisation, not proof of European availability; verify local access. See the FDA approval . Radiation injury depends on dose, fractionation, field and latency; preventive injection series do not guarantee absence of retinopathy.